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GLOBAL HEART
© 2019 World Heart
Federation (Geneva). Pub-
lished by Elsevier Ltd. AllCardiovascular diseases (CVDs) are responsible for
30% of global mortality and contribute substantially to
increased health and economic costs in health care systems.
It is estimated that by 2030, 23.3 million people could die
from CVDs, mainly heart disease or strokes [1]. In the
specific case of Latin America, CVD is the main cause of
disability and death [2], accounting for 35% of all deaths
and 68% of the total disease burden in this region [3].
CVD burden is related to socioeconomic level. A decline
in themortality rate of up to 60%was observed in developed
countries such as the United States or Canada between 1970
and 2000, but in Latin America and the Caribbean, this
decrease was less pronounced [4,5]. The most important
reasons for this phenomenon include failure to control risk
factors, lack of adherence to drugs and procedures of proved
efficacy, and demographic transition [6,7]. The Pan Amer-
ican Health Organization adds that CV mortality rates in
Latin America are very high because of the high prevalence of
CV risk among the population [7].
Primary and secondary CV prevention in high-risk
groups has historically focused on controlling modifiableGLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16risk factors, such as hypertension, dyslipidemia, obesity,
and diabetes, and on correcting unhealthy habits, espe-
cially those with the greatest impact: poor eating habits,
sedentary lifestyle, smoking, and excessive alcohol con-
sumption. However, the data suggest that a complemen-
tary approach to prevention is needed. In this respect, a
significant proportion of morbidity and mortality could be
prevented by implementing population strategies and
accessible and affordable cost-effective interventions, both
for CVD patients and for high-risk individuals [8]. Non-
adherence to medication is a determining factor in the
course of CVD [9], so a strategy that increases observance
of clinical guidelines, fosters access, and improves adher-
ence to medication could play a relevant role. These
concepts led, more than 15 years ago, to the development
of the CV polypill as a strategy to increase drug adherence
and decrease CV morbidity and mortality [10,11].
Several polypills with different components now have
marketing approval, and versions with and without acetyl
salicylic acid (ASA) are available (Table 1) [12]. A polypill
developed by Valentin Fuster and colleagues [13] for3
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4secondary prevention in the CV setting has recently been
approved in more than 30 countries, including several in
Latin America. This polypill contains 3 active principles
with proven CV prevention benefits in a single capsule:
ASA, ramipril, and a statin, which may be atorvastatin or
simvastatin depending on the country where it is mar-
keted. Polypill prescription is a strategy that promotes CV
prevention by improving therapeutic adherence, accessi-
bility, and affordability [13].
Against this backdrop, the purpose of this initiative of
the Inter-American Society of Cardiology is to gather and
present the evidence related to nonadherence as a public
health problem in our countries and specifically address
how polypill as intervention can help in Latin America to
improve CV care, reducing the lack of adherence and
improving CV risk factors’ control.DEVELOPMENT OF THE CONSENSUS STATEMENT
A multidisciplinary team composed of Latin American
experts in the management and prevention of CVD was
convened by the Inter-American Society of Cardiology and
participated in the process and the formulation of state-
ments. A coordinating committee of 2 experts was formed,
along with a recommendation-formulating group thatTABLE 1. Available polypills with marketing approval
Polypill Contents (Marketing Name, Source)
Simvastatin, atenolol, thiazide, ramipril, and ASA (Polycap, Cadila)
Atorvastatin or simvastatin, ramipril, and ASA (Trinomia, Ferrer)
Perindopril, amlodipine, and atorvastatin (Triveram, Servier)
ASA, ramipril, and atorvastatin (Ramitorva, Zydus Cadila)
ASA, losartan, atenolol, and atorvastatin (Starpill, Cipla)
Atorvastatin, ramipril, and clopidogrel (Atamra CV kit, Amra)
Ramipril, metoprolol, atorvastatin, and ASA (CV-Pill kit, Torrent)
Ramipril, atorvastatin, and ASA (RILeAA, East West Pharma)
Ramipril, metoprolol, atorvastatin, and ASA (ZYCAD-4 kit, Zydus
Cadila)
Ramipril, atorvastatin, and ASA (Heart Pill, Excella Pharma)
ASA, atorvastatin, hydrochlorothiazide, and valsartan (Polypill-V,
Alborz Darou)
ASA, atorvastatin, hydrochlorothiazide, and enalapril (Polypill-E,
Alborz Darou)
ASA, acetyl salicylic acid; CV, cardiovascular; RILeAA, ramipril, atorvastatin,
Reproduced with permission from Webster et al. [12].included the coordinating committee, 7 more experts, and
2 consultants who provided advice throughout the entire
process. A content index and a list of 24 relevant clinical
questions (Online Appendix 1) were developed during the
kickoff meeting. A nonsystematic expert search of the
available publications related to these clinically relevant
questions was conducted in September 2016 in appro-
priate databases such as PubMed, Scielo, Lilacs, and others,
giving priority to those that were relevant to Latin America
or conducted in Latin American countries. A total of 87
publications were retrieved. Question 9 required a non-
exhaustive systematic publications review in PubMed per-
formed on September 9, 2016, providing 6 publications
(Online Appendix 2). At the discretion of the coordinating
committee, 61 publications were included after reading the
titles and abstracts of the manuscripts. After these publi-
cations were thoroughly examined, 58 were used by the
recommendation-formulating group to prepare a docu-
ment answering each clinical question that included
potential statements and conclusions. Statements were
debated during a structured in-person meeting. A total of
21 statements and conclusions were included. Statements
that achieved unanimity (100% agreement) or consensus
(80% agreement) were accepted. Statements were
formally categorized with their level of evidence and degreeAvailable Countries
India and Zambia
Argentina, Austria, Belgium, Bosnia and Herzegovina,
Bulgaria, Chile, Czech Republic, Dominican Republic,
Ecuador, El Salvador, Finland, France, Germany,
Greece, Guatemala, Honduras, Ireland, Italy,
Kosovo, Macedonia, Mexico, Moldova, Nicaragua,
Paraguay, Poland, Portugal, Romania, Serbia, Spain,
Sweden, Ukraine, and Uzbekistan
Austria, Belgium, Bulgaria, Croatia, Czech Republic,
Cyprus, Estonia, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, the Netherlands, Poland,
Portugal, Romania, Slovakia, and Slovenia
India
India
India
India
India
India
India
Iran
Iran
and ASA; ZYCAD-4 kit, ramipril, metoprolol, atorvastatin, and ASA.
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TABLE 2. Population-attributable risk for AMI and stroke in men
and women in Latin America
AMI
Total
(%)
Men
(%)
Women
(%)
Abdominal obesity (WHR) 48.5 35.8 63.1
Altered ApoB/ApoA1 40.8 36 46.5
Smoking 38.4 42.5 25.7
Arterial hypertension 32.9 32 15.5
Permanent stress 28.1 32 15.5
Lack of exercise 28 28.1 27.9
Diabetes mellitus 12.9 9.8 22.6
Low consumption of fruit
and vegetables
6.9 7.5 5.5
Stroke
Arterial hypertension 45.2 52.3
Lack of exercise 37.3 32.4
Altered ApoB/ApoA1 25.1 29.2
Unhealthy diet 23.5 22.9
Psychosocial factors 18.5 15
Smoking 16.6 5.3
Abdominal obesity 12.7 25.8
Diabetes 3.7 4.1
AMI, acute myocardial infarction; ApoB/ApoA1, apolipoprotein
Beapolipoprotein A1 ratio; WHR, waist-to-hip ratio.
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of recommendation, according to the SIGN (Scottish
Intercollegiate Guidelines Network 1999e2012) [14]. A
subsequent validation round was performed to increase the
number and geographic distribution of experts. A Delphi-
like process using an online questionnaire presented the
validated statements to a group of 27 additional members
representing 12 national cardiology societies belonging to
the Inter American Society of Cardiology (37 were
approached, representing a 73% of response rate).
LATIN AMERICAN CV SCENARIO
Cardiovascular disease risk factors in Latin
America
In order to understand CVD in Latin America, it is
important to determine the main CV risk factors in the
region. Two large population-based case-control studies
that included Latin American countries have been con-
ducted to identify CV risk factors. The INTERHEART
(Effect of Potentially Modifiable Risk Factors Associated
With Myocardial Infarction) study [2,15] identified factors
associated with acute myocardial infarction (AMI) in
patients from Chile, Colombia, Brazil, and Argentina, and
the INTERSTROKE (Risk Factors for Ischemic and Intra-
cerebral Hemorrhagic Stroke in 22 Countries) study
[16,17] identified factors associated with stroke in patients
from Ecuador, Colombia, Argentina, Brazil, Chile, and
Peru. The most important risk factors for AMI and stroke
in Latin America, according to population-attributable risk
and differentiated by sex, are shown in Table 2.
The CARMELA (Cardiovascular Risk Factor Multiple
Evaluation in Latin America) study assessed the prevalence
of CV risk factors and common carotid far wall intima-
media thickness distributions in 11,550 individuals living
in 7 Latin American cities (Barquisimeto, Venezuela;
Bogota, Colombia; Buenos Aires, Argentina; Lima, Peru;
Mexico City, Mexico; Quito, Ecuador; and Santiago, Chile)
[18,19]. The prevalence of hypertension mirrored the
world average in 3 cities but was lower in the rest. Hy-
percholesterolemia was highly prevalent even in countries
of different socioeconomic levels. The prevalence of dia-
betes was similar to that in the developed countries. The
rate of tobacco use in women living in Santiago and Buenos
Aires was among the highest in the world. Intima-media
thickness and carotid plaque prevalence varied widely
among the participants in the CARMELA cities. On the
basis of the Framingham risk score, 1 in 7 persons showed
a significant risk for a CV event [18,19].
In the PURE (Prospective Urban Rural Epidemiology)
study, although CVD risk factors were lower in low- and
middle-income countries, the rate of major CV events
(death due to AMI, stroke, or heart failure) was higher than
those in high-income countries (5.38 and 6.43 events/
1,000 in habitants/year vs. 3.99 events/1,000 inhabitants/
year, respectively). The case fatality rate was also higher
(15.9% and 17.3% vs. 6.5%). In line with these figures, the
use of preventive drugs and revascularization proceduresGLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16was significantly lower in low- and middle-income coun-
tries [20].
Barriers to cardiovascular drugs in Latin America
In order to reach the goal of a 25% reduction in early CV
mortality by 2025, and as part of the World Health Or-
ganization (WHO) action plan 25  25, at least 50% of
CVD patients must receive essential drugs for secondary
prevention [21]. The current use rate and factors limiting
use must then be determined. The PURE study showed
that to offset these risk factors in Latin America, only
30.1% of CVD patients with a history of myocardial
infarction were receiving ASA, 34.2% beta-blockers, 36%
renin-angiotensin system blockers, and 18.0% statins;
these rates were even lower among patients with previous
stroke. A significant percentage of patients with previous
myocardial infarction (31%) and stroke (54%) received no
medication. Few patients received 3 (4.1%) or 4 (3.3%)
drugs considered to be essential [22]. In high-income
countries, the number of patients who did not receive
any type of drug was 11.2%, compared with 45.1% in
medium- to high-income countries, 69.3% in medium- to
low-income countries, and 80.2% in low-income coun-
tries. National factors (e.g., the country’s economic status)
are more often associated with medication consumption
rates than with personal factors (age, sex, education,
smoking, body mass index, and diabetes) [22,23].
To explain these low treatment rates, it is necessary to
understand that in low- and middle-income countries,5
j gREVIEW
6medicines account for 20% to 60% of health costs,
compared with 18% in countries belonging to the Orga-
nisation for Economic Co-operation and Development
[21]. On the other hand, up to 90% of the population in
developing countries obtains drugs through direct pay-
ments. Specifically in the case of Latin America, an average
of 78% of the whole cost of all medicines is paid out-of-
pocket by the patient [24]. The high price of medicines
can lead to treatment discontinuation or to family debt
and, as a result, access to medicines is limited for a large
part of the world’s population. Medications also represent
an important burden for government budgets [21], data
corroborated by studies conducted in Latin America
[25,26]. Similarly, it was observed that the number of
individuals with previous CVDs (coronary heart disease or
stroke) who had received treatment was higher in
high-income countries than in low-income countries
(antiplatelet agents: 62.0% vs. 8.8%; beta-blockers: 95%
vs. 9.7%; angiotensin-converting enzyme [ACE] inhibitors/
angiotensin receptor blockers: 49.8% vs. 5.2%; statins:
49.5% vs. 3.3%, respectively), with lower treatment rates
in countries with lower per capita income.
Another barrier to the use of CV medications is ther-
apeutic inertia (TI). Several publications [27-29] drew
attention to failures in decision making in the management
of chronic disorders in asymptomatic phases, such as hy-
pertension, dyslipidemia, and diabetes [30]. Failure to
start, intensify, or modify treatment despite clinical
guideline statements is now defined as TI [31]. Two types
of TI have been determined: one occurring before treat-
ment is initiated in the untreated, uncontrolled patient, and
the other during treatment, in the patient who has received
treatment but has not achieved control. The source of TI in
terms of medical performance lies primarily in insufficient
training, lack of knowledge, poor adherence to clinical
guidelines, growing requirements for therapeutic targets,
underutilization of available treatments, and over-
estimation of professional follow-up. Indeed, the medical
act is a constant decision-making process, and to support
this process, clinical guidelines based on scientific evidence
are necessary. Table 3 depicts the conclusions and state-
ments developed by the expert panel on CV risk factors
and barriers to CV medication.
ADHERENCE TO CARDIOVASCULAR MEDICATION
Therapeutic adherence in cardiovascular
prevention
WHO’s adherence project has adopted the following defi-
nition of adherence to long-term therapy: “the extent to
which a person’s behavior—taking medication, following a
diet, and/or executing lifestyle changes, corresponds with
agreed recommendations from a health care provider” [34].
Poor adherence to long-term therapies severely compro-
mises the effectiveness of treatment, making this a critical
issue in population health, both from the perspective of
quality of life and of health economics.Interventions aimed at improving adherence would
provide a significant positive return on investment through
primary prevention (of risk factors) and secondary pre-
vention of adverse health outcome.
Lack of therapeutic adherence has negative effects on
disease prognosis. It increases the risk of new CV events
such as heart attack, stroke, and CV death and leads to
significantly increases in health care costs [9]. In low- and
middle-income countries, as in Latin America, adherence
to medication is lower than in high-income countries [32].
Lack of adherence has been associated with an increase in
long-term CV events, including AMI, stroke, CV mortality,
and all-cause mortality [9,35]. In a meta-analysis con-
ducted with data from the European Union, lack of
adherence was identified as the cause of 13 CVD deaths per
100,000 inhabitants, and 9% of all CVD deaths were
attributed to nonadherence. Conversely, good adherence is
associated with a 20% lower risk of CVD and a 35%
reduction in all-cause mortality [36]. In a study of patients
who had experienced an AMI and received complete
treatment (statins, beta-blockers, and ACE inhibitors),
nonadherent patients did not benefit from the prescription
of any of the 3 classes of drugs; moreover, adherent pa-
tients obtained a significant benefit in reducing new CV
events [37]. In another study that included patients who
had experienced an AMI or had atherosclerosis and were
treated with statins and ACE inhibitors, AMI patients with
full adherence had 27% fewer events than nonadherent
patients did, and 19% fewer events than patients with
partial adherence did. In patients with atherosclerosis, a
44% reduction in events was observed compared with
those in nonadherent patients, and a 24% reduction
compared with those in partially adherent patients [32].Factors that contribute to inadequate patient
adherence to treatment
There is no single individual profile of a nonadherent pa-
tient, because the problem is multifactorial, and at least 4
dimensions influence adherence, all of which interact to a
greater or lesser extent, depending on geographic region,
the country’s gross domestic product (GDP) and the health
system characteristics [35,38]. These dimensions and their
components are as follows [13,39,40]: (1) the patient
dimension, comprising socioeconomic status, age, race,
marital status, income, social support, health care coverage,
educational level, knowledge of the disease, cognitive sta-
tus, and depression; (2) the health care system, comprising
availability, affordability, lack of incentives for health
personnel, and saturation of the system; (3) the disease or
condition, comprising chronicity, duration, absence of
symptoms, and comorbidities; and (4) treatment,
comprising polypharmacy, number of medications and
pills, complexity of the therapeutic regimen, constant
changes, and adverse effects. We can observe these di-
mensions depicted in Figure 1. In terms of economic costs,GLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16
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TABLE 3. Statements and conclusions related to CVD risk factors and barriers to the use of CV drugs in Latin America
No. Statement/Conclusion LE/DR CLA% (n) DLA % (n)
1. According to the results reviewed, the most modifiable risk factors for
cardio-cerebrovascular disease in Latin America are hypertension,
dyslipidemia, abdominal obesity, and smoking [2,15-17].
NA 100 (9) 96 (27)
2. In our region, particularly in low-income countries, <10% of patients with
CVD are receiving treatment with the 3 essential drugs that have
proven useful in secondary prevention [32].
2þþ 100 (9) 93 (27)
3. The GDP and the percentage of health spending in Latin American
countries can be considered as potential barriers for the proper use of
essential drugs in CV prevention [25].
2þ/B 100 (9) 93 (27)
4. In terms of availability, accessibility, and affordability, the following
barriers to access should be taken into account:
 Lack of coverage and fragmentation of health systems.
 High cost of drugs.
 Cost of transportation and distance to the health center.
 Economic status and educational level of the patient.
 Lack of perception by the patient of the severity and importance of
chronic diseases.
(Based on expert opinion.)
4/D 100 (9) 100 (27)
5. Causes of lack of adherence should be identified from a clinical point of
view, and strategies should be implemented to correct them [33].
2þ/C 100 (9) 100 (27)
CLA%, percentage level of agreement in the total votes in the consensus meeting; CV, cardiovascular; CVD, cardiovascular disease; DLA%, per-
centage level of agreement in the total votes in the Delphi-like questionnaire; GDP, gross domestic product; LE/DR, level of evidence/degree of
recommendation; NA, Not applicable.
gREVIEWjlack of adherence is associated with a long-term increment
of $907/year/patient as calculated by Bansilal et al. [38].
At the health system level, although increasing drug
use increases short-term costs, it leads in the long term to a
decrease in the number of significant CV events and costs
associated with hospitalization and treatment of the event.
The net result is a reduction in health care costs. A sys-
tematic review found that adherence >80% is associated
with a lower in expenditure of up to 18% [41]. A mathe-
matical model applied to the economic consequences of
the lack of adherence in chronic diseases showed that long-
term adherence reduces costs of medical care by reducing
hospitalizations and readmissions to the emergency room,
despite the increased pharmaceutical expenditure [42].Control of Risk Factors
Reducon of
CV events?
Improve availability
and affordability POLYPILL
+
FIGURE 1. Barriers to access (red) to cardiovascular (CV) medication and solu-
tions provided by the polypill (orange). In the following diagram, the main
factors affecting adherence are represented in red, like those related to the
health care system, patient, therapy, and finally those related to the disease
condition. Polypill is depicted as a pivotal strategy to improve adherence,
availability and affordability of medication, control of CV risk factors, and
potentially improve the number of CV events.Strategies to improve adherence
The low adherence to prescribed CVD drugs and the
impact on secondary prevention has prompted in-
vestigators to evaluate strategies for improvement. Such
strategies can be implemented through the development
of government health policies and interventions in
routine clinical practice. These interventions can be
classified according to their objective. Informational and
educational interventions target the education of both the
patient and their immediate contacts, while family and
social support interventions aim to improve adherence by
involving the patient’s family or social environment. In-
terventions through group dynamics help increase patientGLOBAL HEART, VOL. 14, NO. 1, 2019 7
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8motivation and follow-up. Behavioral reinforcement in-
terventions can help improve patients’ ability to manage
their treatment, using accountability and self-
management techniques.
Special proactive programs have been shown to be
particularly useful in different clinical situations such as
heart failure and diabetes, improving significantly the rate
of adherence to medication with the consequent reduction
of events in the follow-up period [43,44]. The role of
nurses, pharmacists, and other health agents has been
central in these programs aimed at educating and moni-
toring patients. Its implementation should be cost-effective
particularly in low- and middle-income countries. Its lim-
itation lies in the difficulty of performing them on a large
scale [43,44].
Another useful intervention is treatment simplification,
as it can be assumed that any strategy aimed at simplifying
treatment, such as the polypill, will result in improved
adherence. Finally, nonadherence is a complex phenome-
non with multifactorial origins that requires the combina-
tion of several strategies to obtain the best results [45,46].
In addition to the conventional strategies, new approaches
have also been adopted to achieve treatment persistence:
distribution of informative videos or newsletters by e-mail,
multimedia educational programs, medication review with
the patient, telemedicine or patient monitoring by video,
alarm pill boxes, mobile phone text messages using short
message service or multimedia messaging service, and so
on [45-47]. A recent meta-analysis showed that mobile
phone text messaging approximately doubles the odds of
medication adherence. This increase translates into
adherence rates improving from 50% (assuming this
baseline rate in patients with chronic disease) to 67.8%, or
an absolute increase of 17.8%. Though promising, these
results should be interpreted with caution given the short
duration of trials and reliance on self-reported medication
adherence measures [47].
Some studies have shown that complex interventions
have provided modest improvements and simple in-
terventions have little or no effect. Most strategies show a
loss of efficacy over time, requiring reinforcement strata-
gems [45,46]. It can be assumed that pharmacological
adherence will decrease significantly during the first 6
months after prescription, so these months are a critical
and decisive period for taking action [48]. A review of
publications identified 36 studies with interventions to
improve adherence to CV medications in patients with
hypertension, dyslipidemia, congestive heart failure, and
coronary disease. Of those 36 studies, 17 showed a sig-
nificant improvement in adherence with the use of
behavioral programs, information management, or com-
bined interventions, suggesting that continuous interven-
tion may be necessary for a persistent impact on adherence.
Given the diversity of the included studies, the in-
vestigators stated that the conclusions should be treated
with caution due to the use of indirect comparisons and
questions about possible missed studies, the quality ofincluded data and some review methods (including vote
counting) [49,50].
With regard to strategies simplifying treatment, in-
dividuals treated with the polypill have higher adherence
[51]. Likewise, an opinion survey of CVD patients showed
that prescribing a smaller number of tablets, using cards to
record blood pressure, self-determination of blood pres-
sure measures, and an explanation of the importance of
adherence by the physician are the preferred strategies for
improving pharmacological compliance [52].
Recently, the Spanish consensus document on the
clinical use of the polypill issued a series of statements
related to adherence. Major statements included estab-
lishing good doctor-patient communication and relation-
ships, agreeing on the therapeutic plan with the patient to
improve their commitment and involvement, simplifying
the therapeutic regimen, periodically assessing therapeutic
adherence and implementing adherence reinforcement
strategies over time. This consensus document also un-
derlines the importance of developing effective and
economically affordable drugs and the need for statements
for specific populations, such as the elderly, stroke pa-
tients, among others [53]. Similarly, the 2016 European
guidelines on CV disease prevention [33], the Chilean
Society of Cardiology [54], the Argentine Society of Car-
diology [55], and the Argentine Federation of Cardiology
[56] recommended the use of polypills to increase adher-
ence. Table 4 shows the conclusions and statements
developed by the expert panel about adherence in CV
medication.
POLYPILL: A STRATEGY TO IMPROVE
CARDIOVASCULAR DISEASE IN LATIN AMERICA
Polypill: A strategy to optimize adherence and
accessibility
The idea of combining several active compounds in a single
drug to reduce CV risk was first proposed more than a
decade ago in a document published by WHO [10] and
reinforced later by Wald et al. [11]. This concept has not
only improved therapeutic convenience and adherence,
but it has also optimized health system expenditure.
To date, 4 prospective and randomized clinical trials
including 3,835 patients have reported the effects of the
polypill on adherence, which was 44% higher in the pol-
ypill group than in the control group (74% vs. 53%, 95%
confidence interval [CI]: 1.26 to 1.65) [57,58]. These
findings are particularly significant because the adherence
observed in the comparator groups was significantly higher
than expected and generally reported in community
observational studies, although this may be due to the
Hawthorne (or observer) effect reported in several clinical
trials [59]. Thom et al. [60] reported a study in patients
with CVD in which adherence with the polypill was better
than with the medications administered separately.
Adherence among the group of patients who received the
polypill was 77% compared with 23% (95% CI: 2.74 toGLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16
TABLE 4. Statements and conclusions related to adherence to CV medication
No. Statement/Conclusion LE/DR CLA% (n) DLA % (n)
6. Treatment nonadherence is a complex, multifactorial phenomenon that
includes the following dimensions [13,39,40]:
 Health systemerelated: availability, affordability, lack of incentives for
health personnel, saturation of the health system.
 Disease- or condition-related: chronicity, duration, absence of symptoms,
comorbidities.
 Treatment-related: polypharmacy, number of tablets, complexity of the
treatment, constant changes in regimen, adverse effects.
 Patient-related: age, race, marital status, income level, social support,
health coverage, educational level, knowledge of the disease, cognitive
status, and depression.
In the specific case of CVD, the following barriers are very prevalent:
 Polypharmacy.
 Number of drugs.
 Complexity of therapy.
 Constant changes in the therapeutic regimen.
 Adverse events.
 Absence of perception of both treatment benefit and disease severity by
the patient.
2þþ 100 (9) 100 (27)
7. Lack of adherence leads to a 35% increase in CV risk events. The increased use
of resources derived from these events has a negative impact and raises
the cost of treating CVD. Therefore, it is recommended to prioritize the
implementation of strategies that increase the adherence rate to essential
drugs to reduce CV events and health spending, before implementing new
and expensive therapeutic interventions [36].
1þ/B 100 (9) 100 (27)
8. Lack of adherence should be considered as a risk factor for new CV events.
Individual factors predisposing to lack of adherence should be
systematically investigated in patients who are going to receive chronic CV
prevention treatment. (Based on expert opinion.)
4/D 100 (9) 100 (27)
Abbreviations as in Tables 1 and 3.
gREVIEWj4.09) in the group receiving the usual treatment [60]. The
FOCUS (Fixed-Dose Combination Drug for Secondary
Cardiovascular Prevention) study, which included a large
number of Latin American patients and who used a polypill
composed of ASA, ramipril, and simvastatin, showed a
significant increase in adherence in the group that received
the polypill regimen compared with those receiving con-
ventional treatment (50.8% vs. 41%, respectively)
(P ¼ 0.019; intention-to-treat population) [39].Polypill and control of risk factors
The polypill containing ASA, ramipril, and a statin has
been shown to be equally safe and effective as the same
drugs administered separately for the reduction of blood
pressure (BP) and total cholesterol, with no significant
differences observed at 9 months of follow-up [39]. A
significant reduction in systolic BP of 6.3 mm Hg in the
polypill group compared with the comparator group (95%
CI: 9.03 to 3.64) was reported from 13 studies that
included 7,638 participants. Eleven studies that included
6,565 participants reported significant reductions in totalGLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16cholesterol in the polypill group with levels of 0.61 mmol/l
(95% CI: 0.88 to 0.35). Moreover, the levels low-
density lipoprotein cholesterol (LDL-C) reported from 12
studies and 7,153 participants were lower in the polypill
group by 0.70 mmol/l (95% CI: 0.98 to 0.41). The
authors highlighted that there was a high degree of statis-
tical heterogeneity (I2  80% for all) that could not be
explained, so these results should be considered carefully
[57,58]. In the context of primary prevention, a meta-
analysis that analyzed 6 trials involving 2,200 patients
found that the polypill reduced systolic BP by 9.2 mm Hg
(95% CI: 13.4 to 5.0), diastolic BP by 5.0 mm Hg (95%
CI: 7.4 to 2.6) and total cholesterol by 1.22 mmol/l
(95% CI: 1.60 to 0.84), and LDL-C by 1.02 mmol/l
(95% CI: 1.37 to 0.67). Although tolerance was lower
in those treated with the polypill compared with the pla-
cebo group or those receiving a single component, the
difference was moderate [61]. In the context of secondary
prevention, another meta-analysis analyzing data on 3,140
patients with stable CVD, diabetes, established CVD, or a
calculated risk of CVD >15% at 5 years, use of the polypill
demonstrated better adherence (80% vs. 50%; 95% CI:9
j gREVIEW
101.32 to 1.90) and a significant reduction of systolic BP
of 2.5 mm Hg (95% CI: 4.5 to 0.4) and LDL-C
of 0.1 mmol/l (95% CI: 0.2 to 0.0) when compared
with standard treatment [62].
Evidence for morbidity and mortality
Five studies that included 5,300 participants reported the
effect of the polypill on all-cause mortality and found no
significant difference with the control group, although the
observed frequency of this event was very low (polypill and
control group ¼ 1%; relative risk [RR]: 1.10, 95% CI: 0.64
to 1.89), with a mean follow-up ranging between 9 and 23
months [39,57,60,63-65]. In 6 studies that included 4,517
patients, there were no differences in the rate of fatal and
nonfatal atherosclerotic events, and the incidence was also
low (4.7% in the intervention group vs. 3.7% in the control
group; RR: 1.26; 95% CI: 0.95 to 1.66)
[39,57,60,63,64,66,67]. However, none of the clinical tri-
als published to date were designed to evaluate the impact
of the polypill on the incidence of serious CV events, such
as death, AMI, or stroke.
While waiting for results obtained from studies
designed to collect differences in hard events, evidence of the
benefit of the polypills comes from meta-analysis and
mathematical models. A meta-analysis based on data from 6
primary prevention studies, 21 antihypertensive studies,
and 11 studies with statins, applying an additive mathe-
matical model of RR to the Iranian population, concluded
that a standard polypill formulation composed of ASA, an-
tihypertensives, and statins could prevent 28,500 AMI
deaths and 12,700 stroke deaths [68]. In another study
using a mathematical model to calculate the benefit of pre-
ventive measures in chronic diseases in England and Wales,
the polypill showed a 56% RR reduction for the first AMI or
stroke if treatment was started before age 50 [69]. These
investigators, using a model where a 4-component polypill
had 50% acceptance and 83% adherence, concluded that
990,000 years of life without a first AMI or stroke would be
gained each year in the United Kingdom [70].
Tolerability of polypill
The FOCUS study showed that there were no significant
differences in the frequency of adverse events occurring
between the group receiving the polypill and the group
receiving the 3 drugs separately [39]. A total of 32% of the
patients in the control group and 35% in the polypill group
had an adverse event. The adverse effect was considered
severe in only 6.6% of the control group and 6% of the
polypill group, although the study was not designed to
show differences in this type of events. Four percent of
patients discontinued treatment in both groups. A meta-
analysis showed that patients taking the polypill were
significantly more likely to discontinue medication (20%
vs. 14%; odds ratio: 1.5; 95% CI: 1.2 to 1.9) compared
with patients taking placebo or the components alone,
although this finding was moderate and there were nodifferences among the adverse effects presented (36% vs.
28%; odds ratio: 1.3; 95% CI: 0.7 to 2.5) [61]. In a recently
published Cochrane systematic review analyzing 11 studies
involving 6,906 patients, no significant differences were
found in adverse events reported in the control group and
in the group assigned to the polypill (27.1% vs. 31.4%; RR:
1.16; 95% CI: 1.09 to 1.25) [57].
Polypill and cost-effectiveness
The use of the polypill instead of its separate components
over a 10-year period would prevent a total of 46 nonfatal
and 11 fatal CV events per 1,000 treated patients. The
polypill was also a more effective and cost-effective strat-
egy. The results showed a 90.9% probability that the
polypill is a dominant strategy under the hypothesis that
the health system was willing to pay V30,000 per quality-
adjusted life year (QALY) [71]. The results of a Markov
model using data from a clinical trial analyzing the role of
the polypill in secondary prevention in the United
Kingdom were recently published, and according to the
investigators, preventive strategies can result in a gain in
lifespan of 2 years [72]. In 6 developing regions (as defined
by the World Bank) primary prevention produced an in-
cremental cost-effectiveness ratio of US$746 to US$890/
QALY gained for patients with an absolute CV risk >25%
at 10 years, and US$1,039 to US$1,221/QALY gained for
those with an absolute CV risk >5%. The incremental cost-
effectiveness ratio for secondary prevention ranged from
US$306 to US$388/QALY gained [73]. Another study
evaluated the cost-effectiveness of a polypill composed of 3
antihypertensive drugs, a statin, and ASA for the preven-
tion of CVD in high-risk patients in Latin America. The
lifetime risk of CV disease could be reduced by 15% in
women and 21% in men if the polypill was used by in-
dividuals with a 10-year risk of CV disease 15%.
Achieving this goal would require treating 26% of the
population at a cost of US$34 to US$36 per QALY. Of-
fering the polypill to women with high CV risk and men 55
years of age or older would be the best approach and
would yield an acceptable incremental cost-effectiveness
ratio. The polypill would be very cost-effective even in
the country with the lowest GDP of this study. However,
health policy makers need to balance the value of the
polypill intervention with other interventions, as well as
their country’s willingness and ability to pay for such in-
terventions [74].
Strategies to implement the polypill
In the opinion of experts, strategies that can foster the use
of the polypill can be divided into several levels. First is the
health system level, implemented by improving the
accessibility and affordability of the polypill in all levels of
medical care. Second is the physician level, implemented
by recognizing the consequences of lack of adherence in
CV prevention and achieving the involvement of the doctor
on the problem of nonadherence, systematicallyGLOBAL HEART, VOL. 14, NO. 1, 2019
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investigating it in each consultation identifying it and
decreasing it with therapeutic and educational strategies
such as the use of the polypill, continuing medical edu-
cation, motivating prescribers to achieve adherence objec-
tives (including remuneration for achieving objectives),
promoting this strategy among opinion leaders and scien-
tific societies, and including evidence-based statements for
the use of the polypill in clinical practice guidelines. Third
is the patient level, implemented by educating the patient
on the benefits of using the polypill and involving patient
associations in the implementation of the polypill (level of
evidence: 4 according to SIGN [14]; level of agreement in
the total votes in the consensus meeting: 100%; level of
agreement in the total votes in the Delphi-like question-
naire: 100%). Other statements and conclusions related to
the polypill as a strategy to improve CV disease in Latin
America can be found in Table 5 [75].
POLYPILL: INDICATIONS FOR USE
Clinical scenarios in cardiovascular prevention
The conceptual framework for the development of the
polypill was clear: to promote greater adherence, accessi-
bility, and efficiency of pharmacological treatment in the
largest number of patients worldwide. The recent analysis
of the SPACE (Single Pill to Avert Cardiovascular Events)
studies shows that patients who benefit most from theTABLE 5. Statements and conclusions related to the polypill as strat
No. Statements/Conclusion
9. To optimize therapeutic adherence in the prevention of
actions are recommended [33,45,46,53]:
 Simplify the therapeutic regimen by reducing the num
using the polypill as a public health strategy.
 Incorporate educational initiatives.
 Ensure drug accessibility and affordability.
 Incorporate the use of new technologies such a
electronic devices for patients, text messaging, apps,
10. Several randomized clinical trials have consistently dem
polypill use significantly improves adherence compa
treatment with the same drugs in primary and seco
in different geographic regions, including Latin Ame
11. The polypill reduced blood pressure, total cholesterol,
placebo in the context of primary prevention [61].
12. The polypill demonstrated a significant reduction in sys
pressure, total cholesterol, and LDL-C, and was as eff
drugs administered separately in the context of seco
(patients with stable CVD, diabetes, established CVD
5-yr CVD risk >15%) [62].
13. Therapeutic inertia is an important barrier in the effect
patients with CVD. The use of fixed-dose drug combin
polypill, instead of separate titration of each of the
simple and useful tool for overcoming this problem
opinion.)
LDL-C, low-density lipoprotein cholesterol; other abbreviations as in Table
GLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16polypill intervention, with systolic BP and LDL-C re-
ductions, are those who were not correctly treated at the
beginning of the study [62].
The polypill not only improves patient convenience
and adherence, but it also generates health system savings.
Although no studies have addressed the optimal moment
for starting polypill treatment, experts agree that this
therapy should be evaluated if there are foreseen difficulties
in patient adherence, accessibility to treatment, or moni-
toring. A good time to start may also be after an AMI,
during the hospitalization (if the patient is in a stable
clinical condition), or at discharge, or if a patient has
problems with the therapeutic regimen due to complexity
or number of tablets [53]. Table 6 shows indications for
use of the polypill in primary and secondary prevention.
In addition, treatment with the polypill containing
ASA, ACE inhibitors, and statins could be indicated in
primary prevention patients with a high or very high CV
risk determined by risk charts. Different risk scores have
been proposed and developed in several regions with
different populations around the world. Although none of
them has been calibrated specifically for the population of
Latin America, possibly the one that best suits this region is
the one proposed by WHO because it takes into account
demographic data extracted from American countries.
WHO/International Society of Hypertension riskegy to improve CVD in Latin America
LE/DR CLA% (n) DLA % (n)
CVD, the following
ber of daily doses
s telemonitoring,
etc.
1þ/A 100 (9) 100 (27)
onstrated that
red with standard
ndary prevention
rica [39,60,75].
1þ 100 (9) 100 (27)
and LDL-C versus 1þþ 100 (9) 96 (27)
tolic blood
ective as the same
ndary prevention
, or a calculated
1þþ 100 (9) 96 (27)
ive treatment of
ations and/or the
essential drugs, is
. (Based on expert
4/D 100 (9) 100 (27)
3.
11
TABLE 6. Indications for use of the Polypill in primary and
secondary prevention
Primary prevention
- Patients with a high or very high CV risk determined by
risk charts.
- Diabetic patients older than 50 yrs and at least 1
associated risk factor: smoking, hypertension,
dyslipidemia, high LDL-C, or microalbuminuria.
- Diabetic patients older than 50 yrs with chronic renal
disease and macroalbuminuria or microalbuminuria.
Secondary prevention
- Acute myocardial infarction
- Acute coronary syndromes
- Stable coronary artery disease
- Peripheral artery disease
- Stroke
- Symptomatic and asymptomatic LVD and high CV risk
LVD, left ventricular dysfunction; other abbreviations as in Tables 1
and 5.
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12prediction charts for the Americas (AMR A, B, and D)
predict 10-year risk of a fatal or nonfatal major CV event
(MI or stroke), according to age, sex, BP, smoking status,
total blood cholesterol, and presence or absence of diabetes
mellitus. The polypill could be prescribed in patients with
10-year risk of a fatal or nonfatal CV event 20% [76].
Also, it could be considered in diabetic patients older than
50 years with low risk of bleeding with ASA and at least 1
associated risk factor, including smoking, hypertension,
dyslipidemia, high LDL-C, or microalbuminuria. The data
are based on the HOPE (Heart Outcomes Prevention
Evaluation) study [77], which showed a benefit in the
primary prevention of diabetic patients treated with ram-
ipril, combined with statements from clinical guidelines on
the management of diabetic patients [78], and in diabetic
patients older than 50 years with chronic renal disease and
macroalbuminuria or microalbuminuria [73,74,76].
Finally, the polypill may be of use in patients with high CV
risk and clinical or subclinical ventricular dysfunction, in
whom ramipril would be prescribed for the cardiac
pathology [79] and statin and ASA for the high CV risk.
Polypill: Limitations and contraindications
Two clinical scenarios could be considered. The first is
when therapeutic objectives are not met, and the second is
when adverse effects and/or allergies develop. When the
therapeutic objectives are not achieved, treatment should
be switched to the separate components after ruling out
nonadherence. Also, it may be possible to add extra doses
of other drugs to achieve the objectives in combination
with the polypill. The same strategy could be considered if
intolerance develops to 1 of the components of the polypill
or if a contraindication emerges to any of the components
[53]. Other limitations are related to the possibility of
deteriorating lifestyle habits, if the polypill is perceived bythe patient as a panacea. In this regard, 3 studies (UMPIRE
[Use of a Multidrug Pill in Reducing Cardiovascular
Events], IMPACT (IMProving Adherence using Combina-
tion Therapy), and Kanyini-GAP [Kanyini Guidelines
Adherence With the Polypill] [60,63,64]) collected lifestyle
behavioral data (specifically weight, abdominal circumfer-
ence, body mass index, and duration of physical activity)
and did not find significant differences between patients
treated with the polypill compared with those in the con-
trol group. Statements and conclusions related to the
indication for use of the polypill are depicted in Table 7
[80,81].Discussion
Although the concept of the therapeutic polypill has been
around for a while, its implementation in CVD has been
slow compared with in other diseases for several reasons,
including the resistance of the health systems and physi-
cians to adopt its use. The use of fixed doses with the
consequent impossibility of titration is possibly among the
main barriers in the implementation of the polypill by
physicians. Although in hypertensive patients, the polypill
available in Latin America is available in 2 different doses,
failure to reach the expected goals may be a limitation for
its indication. However, the rate of use of essential drugs in
secondary prevention, especially in low- and middle-
income countries, is so low in our region that even in
suboptimal doses, its use on a large scale would have an
enormous impact in terms of benefit.
The aim of this document was to gather and present
the evidence related to nonadherence as a public health
problem in our countries and specifically to address how
polypill as intervention can help in Latin America to
improve CV care at individual and population levels,
reducing the lack of adherence. This is the main aspect in
which it differs from the other recently published polypill
consensus statements [53].
The clinical questions that served as the basis for this
document were answered with a series of relevant publi-
cations selected by the expert panel and completed with a
nonexhaustive systematic search whenever the recovered
evidence was incomplete. Although this consensus was not
reached exclusively with a systematic review of the publi-
cations, opening up the possibility of selections bias, the
quality of the selected publications ensures a strong
framework, and the subsequent systematic procedure en-
sures that the most important evidence published in the
field is reflected in the document. One issue that emerged
during the preparation of the document is the partial lack
of epidemiological studies focusing on CVDs in Latin
America, so we were forced to use data generated in other
world regions. This type of study must be conducted in the
Latin American setting to allow the medical community
and governments to take informed actions to control the
CVD epidemic in the region. Only then will the implicated
players be able to offer their communities the best optionsGLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16
TABLE 7. Statements and conclusions related to the indication for use of the polypill
No. Statements/Conclusion LE/DR CLA% (n) DLA % (n)
14. Based on study results measuring the impact of increased adherence using
mathematical models, a significant reduction in the number of major CV
events and CV mortality is expected with the use of the polypill.
Studies should be designed and conducted in Latin America to analyze the
impact of increased adherence with the polypill and the corresponding
benefits. (Based on expert opinion.)
4 100 (9) 100 (27)
15. In studies conducted with the polypill, no significant increase is observed
in serious adverse events compared with the drugs administered
separately [39].
1þ 100 (9) 100 (27)
16. In case of an adverse event potentially due to 1 of the components of polypill,
discontinuation of the polypill and identification of the component that
generated the adverse event is recommended. Subsequently, the other
components may be reintroduced and the causative component may be
replaced. (Based on expert opinion.)
4/D 100 (9) 100 (27)
17. According to cost-effectiveness models, the polypill is cost-effective compared
with standard treatment in different settings and would therefore provide
significant savings to health systems in CVD prevention [71,72,74].
4 100 (9) 100 (27)
18. The implementation of a strategy based on the use of the polypill, which
incorporates in single daily dose some of the drugs that have
demonstrated efficacy in CV risk reduction, is recommended for secondary
CV prevention (patients who have presented acute or chronic ischemic
heart disease, revascularized or not, with cerebral or peripheral
atherothrombotic disease), unless any of the components is
contraindicated [80,81].
1þ/A 100 (9) 100 (27)
19. Until results are available from larger studies that demonstrate strong
scientific evidence, the systematic use of the polypill for all patients in
primary prevention is not recommended. However, it may be considered
in high-risk patients with an indication for all the drugs included in the
polypill available in the region. (Based on expert opinion.)
4/D 100 (9) 100 (27)
Abbreviations as in Tables 1 and 3.
gREVIEWjand interventions, tailored to their necessities and expec-
tations, thus fulfilling the main requirements for a suc-
cessful outcome.
The polypill represents a unique opportunity to
implement a public health program based on improving
adherence to existing medicines with proven efficacy and
also to improve accessibility and affordability of these
medicines in Latin America. This intervention could help
relieve the individual and social burden of CVD. The Latin
American countries cannot rely on reductionist solutions to
halt the increase of CVD in the region; instead they must
implement a holistic program that involves several players,
ranging from physicians to governments, who need to
orchestrate the most appropriate response to this
challenge.Conclusions
The expert committee recognizes that nonadherence to
medical therapy is a big problem and recommends the
incorporation of the polypill in public health programs for
CV prevention. Based on the knowledge of the expertGLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16panel, and at the time of writing, the only polypill
approved and available in some Latin American countries
(Argentina, Chile, Dominican Republic, Ecuador, El Sal-
vador, Guatemala, Honduras, Mexico, Nicaragua, and
Paraguay as shown in Table 1) consists of ASA, simvastatin/
atorvastatin, and ramipril (level of evidence: 4; level of
agreement in the total votes in the consensus meeting:
100%; level of agreement in the total votes in the Delphi-
like questionnaire: 100%).
Improving adherence to treatment should be a primary
objective in the attempt to reduce premature CV mortality.
The generation of continuous medical education programs,
the production and dissemination of simple, friendly, and
reliable information for patients and their families and the
simplification of treatments through the polypill, emerge as
powerful strategies in the region. The Inter American So-
ciety of Cardiology is firmly committed to these actions.
Interaction with other organizations in the region such as
the Pan American Health Organization, World Heart
Federation, and Inter American Heart Foundation is
essential in the control of risk factors and the promotion of
CV health. Finally, alliances between scientific societies,13
j gREVIEW
14patient associations, and government are essential to
achieving the 25  25 goal.
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ONLINE APPENDIX 1
Relevant clinical questions developed by the
experts in the kickoff meeting
Q1: What risk factors are associated with cardiovascular
disease and its comorbidities? What is its prevalence in
Latin America?
Q2: What is the clinical impact of the different risk
factors on cardiovascular disease in Latin America?
Q3: Does the GDP of Latin American countries affect
the rate of use of essential drugs for the secondary pre-
vention of cardiovascular disease?
Q4: What is the rate of use of essential drugs for the
secondary prevention of cardiovascular disease in Latin
America?
Q5: In terms of availability, accessibility, and afford-
ability, what barriers exist to access essential drugs for the
secondary prevention of cardiovascular disease in Latin
America?
Q6: What factors determine the lack of therapeutic
adherence in primary and secondary prevention of car-
diovascular disease?
Q7: What consequences have for patients, health care
professionals and the health system the lack of therapeutic
adherence in primary and secondary prevention of car-
diovascular disease?
Q8: What actions can be taken to optimize therapeutic
adherence in prevention of cardiovascular disease?
Q9: How does the therapeutic inertia affect the pre-
vention of cardiovascular disease?
Q10: What benefits are expected from the Polypill in
terms of increasing the therapeutic adherence of patients
subject to primary or secondary cardiovascular prevention?
Q11: What data exist regarding the availability,
accessibility, and affordability of the Polypill?
Q12: From the point of view of the doctor and the
patient what factors can enhance the use of the Polypill?
Q13: What benefits are expected from the Polypill in
terms of controlling the clinical and biochemical parame-
ters of patients subject to cardiovascular prevention?GLOBAL HEART, VOL. 14, NO. 1, 2019
March 2019: 3-16Q14: What benefits are expected from the Polypill in
terms of morbidity and mortality of patients subject to
cardiovascular prevention?
Q15: What benefits are expected from the Polypill in
terms of the rate of adverse effects in patients subject to
cardiovascular prevention?
Q16: What benefits are expected from the Polypill in
terms of the treating cost of patients on cardiovascular
prevention?
Q17: What type of patients could benefit from the
Polypill in secondary prevention?
Q18: What parameters and values define the patient
with high and very high cardiovascular risk?
Q19: What type of patients with high cardiovascular
risk could benefit from the Polypill in primary prevention?
Q20: What type of patients with high cardiovascular
risk could benefit from the three components of the
Polypill in primary prevention?
Q21: How should one act in front of a patient showing
adverse effects to any of the components of the Polypill?
Q22: What are the drawbacks and risks derived from
administering fixed doses through the Polypill?
Q23: In which patient profiles would not be indicated
the use of the Polypill?
Q24: In which moment should the Polypill be
prescribed?ONLINE APPENDIX 2
Search sequence used in PubMed used to gather
information related to question 9
Cardiovascular Diseases[Mesh] AND ("prevention and
control" [Subheading] OR "Secondary Prevention"[Mesh]
OR "Primary Prevention"[Mesh]) AND (("ther-
apy"[Subheading] OR "therapy"[All Fields] OR "treatmen-
t"[All Fields] OR "therapeutics"[MeSH Terms] OR
"therapeutics"[All Fields]) AND inertia[Title]) AND "last 5
years"[PDat] AND (English[lang] OR Spanish[lang])16.e1
